Skip to main content
. 2020 Oct 7;26(3):e403–e413. doi: 10.1002/onco.13536

Figure 1.

Figure 1

Flow diagram of patient inclusion and study examinations. Reasons for stopping treatment due to cardiotoxicity before second evaluation were as follows: acute coronary syndromes (five patients), silent myocardial ischemia (three patients), nonsustained ventricular tachycardia (two patients), and asymptomatic but excessive supraventricular ectopy and atrial fibrillation (one patient).